ZIM Laboratories (NSE:ZIMLAB, BOM:541400) consolidated profit attributable to the owners rose to 44 million Indian rupees in the fiscal third quarter from 40 million rupees a year ago, according to an Indian bourse filing on Wednesday.
Earnings per share for the quarter ended Dec. 31, 2025, climbed to 0.90 rupees from 0.82 rupees a year earlier.
The pharmaceutical company's revenue from operations jumped year on year to 1.09 billion rupees from 963.3 million rupees, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.